Story
Public Health Coalition Sues FDA Over Vaping Enforcement Policy

Summary
A group of prominent health organizations and pediatricians has filed a federal lawsuit against the U.S. Food and Drug Administration, challenging a new policy that allows some unauthorized e-cigarettes to remain on the market.
A coalition of public health organizations, pediatricians, and parents filed a lawsuit against the U.S. Food and Drug Administration on Tuesday, alleging the agency's new enforcement policy for vaping products is unlawful. The complaint, filed in the U.S. District Court in Maryland, targets an FDA guidance from May that permits certain unauthorized e-cigarettes and nicotine pouches to be sold while their marketing applications are under review.
Allegations Against the FDA
The plaintiffs argue that the FDA's policy effectively creates a loophole in federal law. According to the lawsuit, the guidance violates the Tobacco Control Act, which requires products to receive marketing authorization from the agency *before* they can be legally sold.
The group contends the policy was implemented without the legally required public notice and comment period under the Administrative Procedure Act. The lawsuit also challenges the FDA's plan to publish a list of products subject to this enforcement discretion, arguing it would legitimize and facilitate the sale of unauthorized items.
Market Impact and Context
AdThe lawsuit claims the FDA's guidance could allow thousands of unauthorized products to be sold indefinitely, including many of the flavored e-cigarettes and nicotine pouches that are popular with young people. The coalition of plaintiffs includes major health advocacy groups such as:
- The Campaign for Tobacco-Free Kids
- The American Academy of Pediatrics
- The American Cancer Society Cancer Action Network
- The American Heart Association
- The American Lung Association
This legal challenge will be heard in the same Maryland court that invalidated a similar FDA policy in 2017, which had also allowed many e-cigarettes to stay on the market without formal authorization. The FDA did not immediately respond to a request for comment on the lawsuit, according to Reuters.
Read next
More on Stocks
Nike Faces 'Negative Catalyst' as UBS Cuts Price Target on Weakening Demand
UBS has lowered its 12-month price target on Nike, warning that the company is likely to announce significant earnings cuts due to deteriorating demand across key global markets.

Weil, Gotshal & Manges Reportedly Explores Merger Options Following Partner Exits
The prominent law firm is reportedly considering a potential merger and other strategic options after a series of high-profile M&A partner departures, according to a Bloomberg News report.

SpaceX Weighting in Nasdaq 100 to More Than Double to 2.82% in Rebalance
The aerospace company's weighting in the tech-heavy index will jump from 1.28% to 2.82% in a quarterly adjustment, a move that will force passive funds and ETFs to purchase billions of dollars in stock.

US Treasury Secretary Bessent to Meet China's Vice Premier He Lifeng in New York
U.S. Treasury Secretary Scott Bessent and Chinese Vice Premier He Lifeng are set to meet on Sunday at JPMorgan's headquarters to discuss economic issues, including AI security and trade, ahead of a presidential summit.